<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26731">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896115</url>
  </required_header>
  <id_info>
    <org_study_id>A4009</org_study_id>
    <secondary_id>CDM00060272</secondary_id>
    <nct_id>NCT01896115</nct_id>
  </id_info>
  <brief_title>CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation</brief_title>
  <acronym>CUSTOM-DBS</acronym>
  <official_title>Current Steering to Optimize Deep Brain Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <authority>Germany: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare different deep brain stimulation (DBS) settings
      using the commercially approved Boston Scientific Neuromodulation Vercise system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multi-center, double-blind, randomized controlled trial.

      This study will compare various program settings for the bilateral stimulation of the STN
      using the BSC implantable Vercise™ DBS System for the treatment of levodopa-responsive,
      moderate to severe idiopathic PD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Therapeutic window</measure>
    <time_frame>Day 1 programming visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amplitude (mA) difference between full rigidity control threshold and first stimulation induced side effect threshold (eye deviation, muscle contraction, and speech), i.e. &quot;therapeutic window&quot;, at 60 µs and 30 µs pulse width DBS settings (measured in mA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UPDRS III</measure>
    <time_frame>Day 1 programming visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Motor function at 60 µs and 30 µs pulse width DBS settings (measured as UPDRS III score).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Current Steering therapeutic window</measure>
    <time_frame>Day 1 programming visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amplitude (mA) difference between full rigidity control threshold and first stimulation induced side effect threshold at current steering settings (current divided 50% between adjacent electrodes).</description>
  </other_outcome>
  <other_outcome>
    <measure>Current steering motor function</measure>
    <time_frame>Day 1 programming visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Motor function (UPDRS III) at current steering settings</description>
  </other_outcome>
  <other_outcome>
    <measure>Current steering on bradykinesia</measure>
    <time_frame>Day 1 programming visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Severity of bradykinesia at 60 µs, 30 µs, and current steering settings, at efficacy threshold for rigidity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Current steering on tremor</measure>
    <time_frame>Day 1 programming visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Severity of tremor at rest at 60 µs, 30 µs, and current steering settings, at efficacy threshold for rigidity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impedances</measure>
    <time_frame>Day 1 programming visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Electrode impedances at beginning and end of programming session</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Short PW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Vercise DBS system programmed to 30 microseconds pulse width</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional PW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Vercise DBS system programmed to 60 microseconds pulse width</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventral current steering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Vercise DBS system programmed to steer current ventrally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dorsal current steering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Vercise DBS system programmed to steer current dorsally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vercise DBS settings</intervention_name>
    <description>Deep brain stimulation set at short pulse width and monopolar stimulation using current steering</description>
    <arm_group_label>Short PW</arm_group_label>
    <arm_group_label>Conventional PW</arm_group_label>
    <arm_group_label>Ventral current steering</arm_group_label>
    <arm_group_label>Dorsal current steering</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Implanted bilaterally in STN with a Vercise DBS system for Parkinson's disease for at
             least three months with programming optimized according to standard of care.

          -  UPDRS subset III score of ≥30 in the in the pre-operative meds off state.

          -  DBS must improve PD symptoms by ≥30% in the meds off state, as measured by UPDRS
             subset III score.

          -  Medical and mental fitness to comply with programming visit and study related
             procedures.

          -  Able to understand the study requirements and the treatment procedures and provides
             written informed consent before any study-specific tests or procedures are performed.

          -  Off symptom rigidity score of ≥2 in the evaluated arm as determined by the UPDRS-III.

        Exclusion Criteria:

          -  Have any significant medical condition that is likely to interfere with study
             procedures or likely to confound evaluation of study endpoints, including any
             terminal illness with survival &lt;12 months.

          -  Resting and/or action tremor score of ≥3 on the evaluated side as determined by the
             UPDRS-III in pre-operative meds off condition.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Carcieri, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ljubomir Manola</last_name>
    <phone>011-32-241-672-19</phone>
    <email>manolal@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Bowers</last_name>
    <phone>661-949-4175</phone>
    <email>Diane.Bowers@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Scientific Clinical Research Information toll free number</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
    <investigator>
      <last_name>Jens Volkmann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stimulation, implantable pulse generator, deep brain stimulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
